PDF herunterladen
Semin Thromb Hemost 2003; 29(2): 219-226
DOI: 10.1055/s-2003-38838
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Oral Contraceptives and Inherited Thrombophilia: A Gene-Environment Interaction with a Risk of Venous Thrombosis?

Melvin R. Mac Gillavry1 , Martin H. Prins2
  • 1Physician, Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
  • 2Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht, University of Maastricht, Maastricht, The Netherlands
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. April 2003 (online)

    Lizenzen und Reprints

ABSTRACT

There are indications in the literature that asymptomatic women with an inherited thrombophilic defect who use oral contraceptive have an increased risk of venous thrombosis. There are no consistent data regarding the thrombotic risk in users of oral contraceptives with an inherited thrombophilic defect and personal history of venous thrombosis. Selective genetic screening on the basis of clinical judgment, and family and personal history, instead of universal screening, may be useful before oral contraceptives are prescribed. Nonetheless, the actual risks and benefits of such practice remain to be examined.

KEYWORDS

Thrombophilia - oral contraceptives - venous thrombosis - screening

REFERENCES

  • 1 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1993;  353 1167-1173
    PubMedSuche in Google Scholar
  • 2 van Boven H H, Vandenbroucke J P, Briët E, Rosendaal F R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency.  Blood . 1999;  8 2590-2594
    PubMedSuche in Google Scholar
  • 3 Heijboer H, Brandjes D PM, Büller H R, Sturk A, ten Cate W J. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.  N Engl J Med . 1990;  323 1512-1516
    PubMedSuche in Google Scholar
  • 4 Koster T, Rosendaal F R, Briët E. et al . Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study).  Blood . 1995;  85 2756-2761
    PubMedSuche in Google Scholar
  • 5 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci USA . 1993;  90 1004-1008
    CrossrefPubMedSuche in Google Scholar
  • 6 Bertina R M, Koeleman B PC, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
    CrossrefPubMedSuche in Google Scholar
  • 7 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedSuche in Google Scholar
  • 8 Stampfer M J, Malinow M R, Willett W C. et al . A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians.  JAMA . 1992;  268 877-881
    CrossrefPubMedSuche in Google Scholar
  • 9 Falcon C R, Cattaneo M, Panzeri D, Martinelli I, Mannucci P M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.  Arterioscler Thromb . 1994;  14 1080-1083
    PubMedSuche in Google Scholar
  • 10 den Heijer M, Blom H J, Gerrits W B. et al . Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?.  Lancet . 1995;  345 882-885
    CrossrefPubMedSuche in Google Scholar
  • 11 Fermo I, Vigano' D S, Paroni R. et al . Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.  Ann Intern Med . 1995;  123 747-753
    PubMedSuche in Google Scholar
  • 12 den Heijer M, Koster T, Blom H J. et al . Hyperhomocysteinemia as a risk factor for deep vein thrombosis.  N Engl J Med . 1996;  334 759-762
    Suche in Google Scholar
  • 13 Simioni P, Prandoni P, Burlina A. et al . Hyperhomocysteinemia and deep-vein thrombosis. A case-control study.  Thromb Haemost . 1996;  76 883-886
    PubMedSuche in Google Scholar
  • 14 Koster T, Blann A D, Briët E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII and effect of von Willebrand factor on occurrence of deep-vein thrombosis.  Lancet . 1995;  345 152-155
    CrossrefPubMedSuche in Google Scholar
  • 15 Kraaijenhagen R A, in't Anker S P, Koopman M M. et al . High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism.  Thromb Haemost . 2000;  83 5-9
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Vandenbroucke J P, Koster T, Briët E. et al . Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.  Lancet . 1994;  344 1453-1457
    CrossrefPubMedSuche in Google Scholar
  • 17 Bloemenkamp K WM, Rosendaal F R, Büller H R. et al . Enhancement by factor V Leiden of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen.  Lancet . 1995;  346 1593-1596
    CrossrefPubMedSuche in Google Scholar
  • 18 Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population.  J Intern Med . 1992;  232 155-160
    PubMedSuche in Google Scholar
  • 19 Anderson F A, Wheeler H B, Goldberg R J. et al . A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.  Arch Intern Med . 1991;  151 933-938
    CrossrefPubMedSuche in Google Scholar
  • 20 Vandenbroucke J P, van der Meer J M F, Helmerhorst F M, RosendaalFR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?.  BMJ . 1996;  313 1127-1130
    CrossrefPubMedSuche in Google Scholar
  • 21 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet . 1995;  346 1133-1134
    CrossrefPubMedSuche in Google Scholar
  • 22 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening.  JAMA . 1997;  277 1305-1307
    CrossrefPubMedSuche in Google Scholar
  • 23 Rosendaal F R, Doggen C J, Zivelin A. et al . Geographic distribution of the 20210 G to A prothrombin variant.  Thromb Haemost . 1998;  79 706-708
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Tait R C, Walker I D, Perry D J. et al . Prevalence of antithrombin deficiency in the healthy population.  Br J Haematol . 1994;  87 106-112
    CrossrefPubMedSuche in Google Scholar
  • 25 Tait R C, Walker I D, Reitsma P H. et al . Prevalence of protein C deficiency in the healthy population.  Thromb Haemost . 1995;  73 87-93
    PubMedSuche in Google Scholar
  • 26 Pabinger I, Brucker S, Kyrle P A. et al . Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening.  Blood Coagul Fibrinolysis . 1992;  3 547-553
    PubMedSuche in Google Scholar
  • 27 Cumming A M, Keeney S, Salden A. et al . The prothrombin gene G20210A variant: prevalence in a U.K  anticoagulant clinic population. Br J Haematol . 1997;  98 353-355
    CrossrefPubMedSuche in Google Scholar
  • 28 Gladson C L, Scharrer I, Hach V, Beck K H, Griffin J H. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.  Thromb Haemost . 1988;  59 18-22
    PubMedSuche in Google Scholar
  • 29 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel.  Thromb Haemost . 1989;  61 50-54
    PubMedSuche in Google Scholar
  • 30 Schattner A, Kasher I, Berrebi A. Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years.  QJM . 1998;  90 283-287
    PubMedSuche in Google Scholar
  • 31 Allaart C F, Poort S R, Rosendaal F R. et al . Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect.  Lancet . 1993;  341 134-138
    CrossrefPubMedSuche in Google Scholar
  • 32 van den Belt G M A, Prins M H, Huisman M V, Hirsh J. Familial thrombophilia: a review analysis.  Clin Appl Thromb Hemost . 1996;  2 227-236
    PubMedSuche in Google Scholar
  • 33 Simioni P, Sanson B J, Prandoni P. et al . Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost . 1999;  81 198-202
    PubMedSuche in Google Scholar
  • 34 Pabinger I, Kyrle P A, Heistinger M. et al . The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study.  Thromb Haemost . 1994;  71 441-445
    PubMedSuche in Google Scholar
  • 35 Sanson B J, Simioni P, Prins M H, on behalf of the TACT-study group. The incidence of venous thromboembolism in asymtomatic carriers of a marker of thrombophilia.  Blood . 1999;  94 3702-3706
    PubMedSuche in Google Scholar
  • 36 De Stefano V, Leone G, Mastrangelo S. et al . Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S.  Thromb Haemost . 1994;  72 352-358
    PubMedSuche in Google Scholar
  • 37 van den Belt G M A, Sanson B J, Simioni P. et al . Recurrence of venous thromboembolism in patients with familial thrombophilia.  Arch Intern Med . 1997;  157 2227-2232
    CrossrefPubMedSuche in Google Scholar
  • 38 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet . 1993;  342 1503-1506
    CrossrefPubMedSuche in Google Scholar
  • 39 Ridker P M, Hennekens C H, Lindpainter K. et al . Mutation in the gene encoding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.  N Engl J Med . 1995;  332 912-917
    CrossrefPubMedSuche in Google Scholar
  • 40 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene.  Br J Haematol . 1997;  98 907-909
    CrossrefPubMedSuche in Google Scholar
  • 41 Middeldorp S, Henkens C MA, Koopman M MW. et al . The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.  Ann Intern Med . 1998;  128 15-20
    CrossrefPubMedSuche in Google Scholar
  • 42 Ridker P M, Glynn R J, Miletich J P. et al . Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.  Ann Intern Med . 1997;  126 528-531
    CrossrefPubMedSuche in Google Scholar
  • 43 Middeldorp S, Meinardi J R, Koopman M MW. et al . A prospective study on the incidence of clinically overt venous thromboembolism in asymptomatic carriers of the FV:Q506 mutation (Abst).  Thromb Haemost . 1999;  82 418
    PubMedSuche in Google Scholar
  • 44 Simioni P, Prandoni P, Girolami A. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation (letter).  Ann Intern Med . 1999;  130 538
    PubMedSuche in Google Scholar
  • 45 Middeldorp S, Meinardi J R, van Thienen V J. et al . The incidence of venous thromboembolism in relatives of patients with the prothrombin 20210A mutation (Abst).  Thromb Haemost . 1999;  82 277
    PubMedSuche in Google Scholar
  • 46 Ridker P M, Miletich J P, Stampfer M J. et al . Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation . 1995;  92 2800-2802
    CrossrefPubMedSuche in Google Scholar
  • 47 Simioni P, Prandoni P, Lensing A W. et al . The risk of recurrent venous thromboembolism in patients with an Arg506/ Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med . 1997;  336 399-403
    CrossrefPubMedSuche in Google Scholar
  • 48 Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden.  Thromb Haemost . 1996;  75 229-232
    PubMedSuche in Google Scholar
  • 49 Eichinger S, Pabinger I, Stümpflen A. et al . The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.  Thromb Haemost . 1997;  77 624-628
    PubMedSuche in Google Scholar
  • 50 Eichinger S, Minar E, Hirschl M. et al . The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.  Thromb Haemost . 1999;  81 14-17
    PubMedSuche in Google Scholar
  • 51 O'Donnell J, Tuddenham E G, Manning R. et al . High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase protein.  Thromb Haemost . 1997;  77 825-828
    PubMedSuche in Google Scholar
  • 52 Eichinger S, Stümpflen A, Hirschl M. et al . Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.  Thromb Haemost . 1998;  80 566-569
    PubMedSuche in Google Scholar
  • 53 Kyrle P A, Minar E, Hirschl M. et al . High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.  N Engl J Med . 2000;  343 457-462
    CrossrefPubMedSuche in Google Scholar
  • 54 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.  Lancet . 1995;  346 1575-1582
    PubMedSuche in Google Scholar
  • 55 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.  Lancet . 1995;  346 1589-1593
    CrossrefPubMedSuche in Google Scholar
  • 56 Lewis M A, Heinemann L AJ, MacRae K D, Bruppacher R, Spitzer W O. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research (erratum: Contraception 1996;54:121).  Contraception . 1996;  54 5-13
    CrossrefPubMedSuche in Google Scholar
  • 57 Spitzer W O, Lewis M A, Heinemann L J, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study.  BMJ . 1996;  312 83-88
    PubMedSuche in Google Scholar
  • 58 Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study.  Contraception . 1998;  57 291-301
    CrossrefPubMedSuche in Google Scholar
  • 59 Vasilakis C, Jick S S, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills.  Contraception . 1999;  59 79-83
    CrossrefPubMedSuche in Google Scholar
  • 60 Parkin L, Skegg D CG, Wilson M, Herbison G P, Paul C. Oral contraceptives and fatal pulmonary embolism.  Lancet . 2000;  355 2133-2134
    CrossrefPubMedSuche in Google Scholar
  • 61 Bloemenkamp K WM, Rosendaal F R, Büller H R. et al . Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias.  Arch Intern Med . 1999;  159 65-70
    CrossrefPubMedSuche in Google Scholar
  • 62 Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.  J Intern Med . 1998;  244 27-32
    PubMedSuche in Google Scholar
  • 63 Andersen B S, Olsen J, Nielsen G L. et al . Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism.  Thromb Haemost . 1998;  79 23-31
    PubMedSuche in Google Scholar
  • 64 Herings R MC, Urquhart J, Leufkens H GM. Venous thromboembolism among new users of different oral contraceptives (Erratum: Lancet 1999;354:1478).  Lancet . 1999;  354 127-128
    CrossrefPubMedSuche in Google Scholar
  • 65 Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone.  Lancet . 1999;  354 1610-1611
    PubMedSuche in Google Scholar
  • 66 Burnhill M S. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.  Int J Fertil Womens Med . 1999;  44 19-30
    PubMedSuche in Google Scholar
  • 67 Farmer R DT, Lawrenson R A, Thompson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.  Lancet . 1997;  349 83-88
    CrossrefPubMedSuche in Google Scholar
  • 68 Farmer R DT, Todd J C, MacRae K D, Williams T J, Lewis M A. Oral contraception was not associated with venous thromboembolic disease in recent study.  BMJ . 1998;  316 1090
    PubMedSuche in Google Scholar
  • 69 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.  Arterioscler Thromb Vasc Biol . 1999;  19 700-703
    CrossrefPubMedSuche in Google Scholar
  • 70 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.  Arch Intern Med . 2000;  160 49-52
    CrossrefPubMedSuche in Google Scholar
  • 71 Spannagl M, Heinemann L AJ, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?.  Eur J Contracept Reprod Health Care . 2000;  5 105-112
    CrossrefPubMedSuche in Google Scholar
  • 72 Bloemenkamp K WM, Helmerhorst F M, Rosendaal F RR, Vandenbroucke J P. Venous thrombosis, oral contraceptives and high factor VIII levels.  Thromb Haemost . 1999;  82 1024-1027
    PubMedSuche in Google Scholar
  • 73 Creinin M D, Lisman R, Strickler R C. Screening for factor V Leiden mutation before prescribing combination oral contraceptives.  Fertil Steril . 1999;  72 646-651
    CrossrefPubMedSuche in Google Scholar
  • 74 Palareti G, Legnani C, Frascaro M. et al . Screening for activated protein C resistance before oral contraceptive treatment: a pilot study.  Contraception . 1999;  59 293-299
    CrossrefPubMedSuche in Google Scholar
  • 75 Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study.  BMJ . 2001;  322 1024-1025
    CrossrefPubMedSuche in Google Scholar